Literature DB >> 34385184

Radiation-Induced Phosphorylation of a Prion-Like Domain Regulates Transformation by FUS-CHOP.

Mark Chen1,2, Joseph P Foster3, Ian C Lock1, Nathan H Leisenring1, Andrea R Daniel4, Warren Floyd1,2, Eric Xu4, Ian J Davis5,6,7, David G Kirsch8,4.   

Abstract

Chromosomal translocations generate oncogenic fusion proteins in approximately one-third of sarcomas, but how these proteins promote tumorigenesis is not well understood. Interestingly, some translocation-driven cancers exhibit dramatic clinical responses to therapy, such as radiotherapy, although the precise mechanism has not been elucidated. Here we reveal a molecular mechanism by which the fusion oncoprotein FUS-CHOP promotes tumor maintenance that also explains the remarkable sensitivity of myxoid liposarcomas to radiation therapy. FUS-CHOP interacted with chromatin remodeling complexes to regulate sarcoma cell proliferation. One of these chromatin remodelers, SNF2H, colocalized with FUS-CHOP genome-wide at active enhancers. Following ionizing radiation, DNA damage response kinases phosphorylated the prion-like domain of FUS-CHOP to impede these protein-protein interactions, which are required for transformation. Therefore, the DNA damage response after irradiation disrupted oncogenic targeting of chromatin remodelers required for FUS-CHOP-driven sarcomagenesis. This mechanism of disruption links phosphorylation of the prion-like domain of an oncogenic fusion protein to DNA damage after ionizing radiation and reveals that a dependence on oncogenic chromatin remodeling underlies sensitivity to radiation therapy in myxoid liposarcoma. SIGNIFICANCE: Prion-like domains, which are frequently translocated in cancers as oncogenic fusion proteins that drive global epigenetic changes, confer sensitivity to radiation via disruption of oncogenic interactions. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34385184      PMCID: PMC8487964          DOI: 10.1158/0008-5472.CAN-20-1497

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   13.312


  36 in total

1.  Additional evidence of a variant translocation t(12;22) with EWS/CHOP fusion in myxoid liposarcoma: clinicopathological features.

Authors:  P Dal Cin; R Sciot; I Panagopoulos; P Aman; I Samson; N Mandahl; F Mitelman; H Van den Berghe; C D Fletcher
Journal:  J Pathol       Date:  1997-08       Impact factor: 7.996

2.  Transcription Factors Activate Genes through the Phase-Separation Capacity of Their Activation Domains.

Authors:  Ann Boija; Isaac A Klein; Benjamin R Sabari; Alessandra Dall'Agnese; Eliot L Coffey; Alicia V Zamudio; Charles H Li; Krishna Shrinivas; John C Manteiga; Nancy M Hannett; Brian J Abraham; Lena K Afeyan; Yang E Guo; Jenna K Rimel; Charli B Fant; Jurian Schuijers; Tong Ihn Lee; Dylan J Taatjes; Richard A Young
Journal:  Cell       Date:  2018-11-15       Impact factor: 41.582

3.  Tumor-specific retargeting of an oncogenic transcription factor chimera results in dysregulation of chromatin and transcription.

Authors:  Mukund Patel; Jeremy M Simon; Michael D Iglesia; Sam B Wu; Andrew W McFadden; Jason D Lieb; Ian J Davis
Journal:  Genome Res       Date:  2011-11-15       Impact factor: 9.043

4.  Exomic analysis of myxoid liposarcomas, synovial sarcomas, and osteosarcomas.

Authors:  Christine G Joseph; Heejung Hwang; Yuchen Jiao; Laura D Wood; Isaac Kinde; Jian Wu; Nils Mandahl; Jinyong Luo; Ralph H Hruban; Luis A Diaz; Tong-Chuan He; Bert Vogelstein; Kenneth W Kinzler; Fredrik Mertens; Nickolas Papadopoulos
Journal:  Genes Chromosomes Cancer       Date:  2013-11-05       Impact factor: 5.006

5.  Excellent local control rates and distinctive patterns of failure in myxoid liposarcoma treated with conservation surgery and radiotherapy.

Authors:  B Ashleigh Guadagnolo; Gunar K Zagars; Matthew T Ballo; Shreyaskumar R Patel; Valerae O Lewis; Robert S Benjamin; Raphael E Pollock
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-09-24       Impact factor: 7.038

6.  Radiosensitivity translates into excellent local control in extremity myxoid liposarcoma: a comparison with other soft tissue sarcomas.

Authors:  Peter W M Chung; Benjamin M Deheshi; Peter C Ferguson; Jay S Wunder; Anthony M Griffin; Charles N Catton; Robert S Bell; Lawrence M White; Rita A Kandel; Brian O'Sullivan
Journal:  Cancer       Date:  2009-07-15       Impact factor: 6.860

7.  A novel effector domain from the RNA-binding protein TLS or EWS is required for oncogenic transformation by CHOP.

Authors:  H Zinszner; R Albalat; D Ron
Journal:  Genes Dev       Date:  1994-11-01       Impact factor: 11.361

8.  FET family fusion oncoproteins target the SWI/SNF chromatin remodeling complex.

Authors:  Malin Lindén; Christer Thomsen; Pernilla Grundevik; Emma Jonasson; Daniel Andersson; Rikard Runnberg; Soheila Dolatabadi; Christoffer Vannas; Manuel Luna Santamarίa; Henrik Fagman; Anders Ståhlberg; Pierre Åman
Journal:  EMBO Rep       Date:  2019-04-08       Impact factor: 8.807

9.  Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool.

Authors:  Edward Y Chen; Christopher M Tan; Yan Kou; Qiaonan Duan; Zichen Wang; Gabriela Vaz Meirelles; Neil R Clark; Avi Ma'ayan
Journal:  BMC Bioinformatics       Date:  2013-04-15       Impact factor: 3.169

10.  Combined experience of six independent laboratories attempting to create an Ewing sarcoma mouse model.

Authors:  Tsion Zewdu Minas; Didier Surdez; Tahereh Javaheri; Miwa Tanaka; Michelle Howarth; Hong-Jun Kang; Jenny Han; Zhi-Yan Han; Barbara Sax; Barbara E Kream; Sung-Hyeok Hong; Haydar Çelik; Franck Tirode; Jan Tuckermann; Jeffrey A Toretsky; Lukas Kenner; Heinrich Kovar; Sean Lee; E Alejandro Sweet-Cordero; Takuro Nakamura; Richard Moriggl; Olivier Delattre; Aykut Üren
Journal:  Oncotarget       Date:  2017-05-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.